{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:49:26Z","timestamp":1787496566161,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22761-1","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:29:38Z","timestamp":1762349378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Microbiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8921-0957","authenticated-orcid":false,"given":"Chinna Babu","family":"Dracham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Bandanatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Ravi Kiran","family":"Dumpala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveena","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Kotlapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayalakshmi","family":"Juturu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokeswari","family":"Annam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"4","key":"22761_CR1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld, A. G. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4), e56-93. https:\/\/doi.org\/10.1093\/cid\/cir073 (2011). PMID: 21258094.","journal-title":"Clin Infect Dis"},{"key":"22761_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-200262001-00001","volume":"62 Suppl 1","author":"DC Dale","year":"2002","unstructured":"Dale, D. C. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 62 Suppl 1, 1\u201315. https:\/\/doi.org\/10.2165\/00003495-200262001-00001 (2002). PMID: 12479591.","journal-title":"Drugs"},{"issue":"8","key":"22761_CR3","doi-asserted-by":"publisher","first-page":"e42843","DOI":"10.7759\/cureus.42843","volume":"15","author":"R Raheja","year":"2023","unstructured":"Raheja, R. et al. Classification of Chemotherapy-Induced febrile neutropenic episodes into one of the three febrile neutropenic syndromes. Cureus 15 (8), e42843. https:\/\/doi.org\/10.7759\/cureus.42843 (2023). PMID: 37664262; PMCID: PMC10472482.","journal-title":"Cureus"},{"issue":"suppl 5","key":"22761_CR4","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky, J. et al. ESMO guidelines committee. management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 27(suppl 5), v111\u2013v118. https:\/\/doi.org\/10.1093\/annonc\/mdw325 (2016). PMID: 27664247.","journal-title":"Ann Oncol."},{"issue":"Suppl 5","key":"22761_CR5","doi-asserted-by":"publisher","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","volume":"21","author":"J de Naurois","year":"2010","unstructured":"de Naurois, J. et al. ESMO Guidelines Working Group: Management of febrile neutropenia\u2014ESMO clinical practice guidelines. Ann Oncol. 21(Suppl 5), v252-6. https:\/\/doi.org\/10.1093\/annonc\/mdq196 (2010). PMID: 20555092.","journal-title":"Ann Oncol."},{"issue":"5","key":"22761_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","volume":"20","author":"EA Griffiths","year":"2022","unstructured":"Griffiths, E. A. et al. NCCN Guidelines\u00ae Insights: Hematopoietic Growth Factors, Version 1.2022. J Natl Compr Canc Netw. 20(5), 436\u2013442. https:\/\/doi.org\/10.6004\/jnccn.2022.0026 (2022). PMID: 35545171.","journal-title":"J Natl Compr Canc Netw."},{"issue":"3","key":"22761_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.15406\/jcpcr.2016.05.00165","volume":"5","author":"A Rasmy","year":"2016","unstructured":"Rasmy, A. et al. Febrile neutropenia in cancer patient: epidemiology, microbiology, pathophysiology and management. J. Cancer Prev. Curr. Res. 5 (3), 273\u2013278. https:\/\/doi.org\/10.15406\/jcpcr.2016.05.00165 (2016).","journal-title":"J. Cancer Prev. Curr. Res."},{"issue":"2","key":"22761_CR8","doi-asserted-by":"publisher","first-page":"e14236","DOI":"10.1111\/tid.14236","volume":"26","author":"EJ Stohs","year":"2024","unstructured":"Stohs, E. J., Abbas, A. & Freifeld, A. Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies. Transpl. Infect. Dis. 26 (2), e14236. https:\/\/doi.org\/10.1111\/tid.14236 (2024). PMID: 38349035.","journal-title":"Transpl. Infect. Dis."},{"key":"22761_CR9","unstructured":"Zuckermann, J. et al. Microbiological findings in febrile neutropenic patients in a tertiary hospital of Southern Brazil. Clin Biomed Res. 32 (3).\u00a0https:\/\/seer.ufrgs.br\/index.php\/hcpa\/article\/view\/29006 (2012)."},{"key":"22761_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12885-016-2408-9","volume":"16","author":"S Zhang","year":"2016","unstructured":"Zhang, S., Liang, F. & Tannock, I. Use and misuse of common terminology criteria for adverse events in cancer clinical trials. BMC Cancer. 16, 392. https:\/\/doi.org\/10.1186\/s12885-016-2408-9 (2016). PMID: 27377548; PMCID: PMC4932726.","journal-title":"BMC Cancer"},{"issue":"1","key":"22761_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1186\/s12885-021-08258-w","volume":"21","author":"R Mahtani","year":"2021","unstructured":"Mahtani, R. et al. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety. BMC Cancer. 21 (1), 621. https:\/\/doi.org\/10.1186\/s12885-021-08258-w (2021). PMID: 34044798; PMCID: PMC8157684.","journal-title":"BMC Cancer"},{"issue":"6","key":"22761_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/bjh.13358","volume":"169","author":"V Bozzoli","year":"2015","unstructured":"Bozzoli, V. et al. Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma. Br. J. Haematol. 169 (6), 787\u2013794. https:\/\/doi.org\/10.1111\/bjh.13358 (2015). PMID: 25819007.","journal-title":"Br. J. Haematol."},{"issue":"6","key":"22761_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/COC.0000000000000141","volume":"37","author":"L Balducci","year":"2014","unstructured":"Balducci, L., Mo, M., Abella, E. & Saven, A. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim. Am J Clin Oncol. 37(6), 603\u201310. https:\/\/doi.org\/10.1097\/COC.0000000000000141 (2014). PMID: 25350463.","journal-title":"Am J Clin Oncol."},{"issue":"10","key":"22761_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1097\/CAD.0000000000000279","volume":"26","author":"Y Hashiguchi","year":"2015","unstructured":"Hashiguchi, Y. et al. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs. 26 (10), 1054\u20131060. https:\/\/doi.org\/10.1097\/CAD.0000000000000279 (2015). PMID: 26267078; PMCID: PMC4588600.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"22761_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/diseases7020041","volume":"7","author":"M Gajd\u00e1cs","year":"2019","unstructured":"Gajd\u00e1cs, M. & Urb\u00e1n, E. Epidemiological trends and resistance associated with Stenotrophomonas maltophilia bacteremia: A 10-Year retrospective cohort study in a Tertiary-Care hospital in Hungary. Diseases 7 (2), 41. https:\/\/doi.org\/10.3390\/diseases7020041 (2019). PMID: 31159258; PMCID: PMC6631814.","journal-title":"Diseases"},{"issue":"2","key":"22761_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/antibiotics8020052","volume":"8","author":"M Gajd\u00e1cs","year":"2019","unstructured":"Gajd\u00e1cs, M. The continuing threat of methicillin-resistant Staphylococcus aureus. Antibiotics (Basel) 8(2), 52. https:\/\/doi.org\/10.3390\/antibiotics8020052 (2019). PMID: 31052511; PMCID: PMC6627156.","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"22761_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12879-023-08058-6","volume":"23","author":"N Joudeh","year":"2023","unstructured":"Joudeh, N. et al. Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country. BMC Infect. Dis. 23 (1), 106. https:\/\/doi.org\/10.1186\/s12879-023-08058-6 (2023). PMID: 36814229; PMCID: PMC9944765.","journal-title":"BMC Infect. Dis."},{"key":"22761_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1471-2334-11-183","volume":"11","author":"JP Lanoix","year":"2011","unstructured":"Lanoix, J. P. et al. Bacterial infection profiles in lung cancer patients with febrile neutropenia. BMC Infect. Dis. 11, 183. https:\/\/doi.org\/10.1186\/1471-2334-11-183 (2011). PMID: 21707992; PMCID: PMC3147018.","journal-title":"BMC Infect. Dis."},{"issue":"4","key":"22761_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/jac\/dki028","volume":"55","author":"M Paul","year":"2005","unstructured":"Paul, M., Borok, S., Fraser, A., Vidal, L. & Leibovici, L. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 55 (4), 436\u2013444. https:\/\/doi.org\/10.1093\/jac\/dki028 (2005). PMID: 15722392.","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl 1","key":"22761_CR20","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.ijantimicag.2007.06.012","volume":"30","author":"J Klastersky","year":"2007","unstructured":"Klastersky, J. et al. Bacteraemia in febrile neutropenic cancer patients. Int. J. Antimicrob. Agents. 30 (Suppl 1), S51\u2013S59. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.06.012 (2007). PMID: 17689933.","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"6","key":"22761_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ijid.2007.02.002","volume":"11","author":"ND Baskaran","year":"2007","unstructured":"Baskaran, N. D., Gan, G. G., Adeeba, K. & Sam, I. C. Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia. Int. J. Infect. Dis. 11 (6), 513\u2013517. https:\/\/doi.org\/10.1016\/j.ijid.2007.02.002 (2007). PMID: 17459753.","journal-title":"Int. J. Infect. Dis."},{"issue":"Suppl 1","key":"22761_CR22","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.ijantimicag.2008.06.017","volume":"32","author":"R Feld","year":"2008","unstructured":"Feld, R. Bloodstream infections in cancer patients with febrile neutropenia. Int. J. Antimicrob. Agents. 32 (Suppl 1), S30\u2013S33. https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.06.017 (2008). PMID: 18778919.","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"22761_CR23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4103\/0019-509X.175330","volume":"51","author":"LA Jacob","year":"2014","unstructured":"Jacob, L. A. et al. Clinical and microbiological profile of febrile neutropenia in solid tumors and hematological malignancies at a tertiary cancer care center in South India. Indian J Cancer. 51(4), 464\u20138. https:\/\/doi.org\/10.4103\/0019-509X.175330 (2014). PMID: 26842163.","journal-title":"Indian J Cancer."},{"issue":"3","key":"22761_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/0971-5851.190352","volume":"37","author":"KG Babu","year":"2016","unstructured":"Babu, K. G. et al. Bloodstream infections in febrile neutropenic patients at a tertiary cancer Institute in South india: A timeline of clinical and microbial trends through the years. Indian J. Med. Paediatr. Oncol. 37 (3), 174\u2013182 (2016). PMID: 27688611; PMCID: PMC5027790.","journal-title":"Indian J. Med. Paediatr. Oncol."},{"issue":"8","key":"22761_CR25","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1086\/378305","volume":"37","author":"D Yadegarynia","year":"2003","unstructured":"Yadegarynia, D., Tarrand, J., Raad, I. & Rolston, K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis. 37(8), 1144\u20135. https:\/\/doi.org\/10.1086\/378305 (2003). PMID: 14523785.","journal-title":"Clin Infect Dis."},{"issue":"10","key":"22761_CR26","doi-asserted-by":"publisher","first-page":"e0224299","DOI":"10.1371\/journal.pone.0224299","volume":"14","author":"RL Parodi","year":"2019","unstructured":"Parodi, R. L. et al. A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period. PLoS One. 14 (10), e0224299. https:\/\/doi.org\/10.1371\/journal.pone.0224299 (2019). PMID: 31671108; PMCID: PMC6822758.","journal-title":"PLoS One"},{"issue":"1","key":"22761_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s15010-013-0525-9","volume":"42","author":"L Nesher","year":"2014","unstructured":"Nesher, L. & Rolston, K. V. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 42 (1), 5\u201313. https:\/\/doi.org\/10.1007\/s15010-013-0525-9 (2014). PMID: 23975584.","journal-title":"Infection"},{"issue":"1","key":"22761_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12879-022-07375-6","volume":"22","author":"R Rabayah","year":"2022","unstructured":"Rabayah, R. et al. Microbial spectrum and drug resistance profile in solid malignancies in a large tertiary hospital from Palestine. BMC Infect. Dis. 22 (1), 385. https:\/\/doi.org\/10.1186\/s12879-022-07375-6 (2022). PMID: 35436875; PMCID: PMC9014612.","journal-title":"BMC Infect. Dis."},{"issue":"6","key":"22761_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3349\/ymj.2021.62.6.479","volume":"62","author":"D Kim","year":"2021","unstructured":"Kim, D., Lee, S., Youk, T. & Hong, S. Incidence and clinical outcomes of febrile neutropenia in adult cancer patients with chemotherapy using Korean nationwide health insurance database. Yonsei Med. J. 62 (6), 479\u2013486. https:\/\/doi.org\/10.3349\/ymj.2021.62.6.479 (2021). PMID: 34027634; PMCID: PMC8149937.","journal-title":"Yonsei Med. J."},{"issue":"9","key":"22761_CR30","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1002\/cam4.2955","volume":"9","author":"T Aagaard","year":"2020","unstructured":"Aagaard, T. et al. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. Cancer Med. 9 (9), 3033\u20133042. https:\/\/doi.org\/10.1002\/cam4.2955 (2020). PMID: 32144897; PMCID: PMC7196064.","journal-title":"Cancer Med."},{"issue":"4","key":"22761_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4103\/0019-509X.175303","volume":"51","author":"R Rajendranath","year":"2014","unstructured":"Rajendranath, R. et al. Factors predicting outcome in high risk febrile neutropenia in patients receiving intensive chemotherapy for acute sleukemia: A prospective, observational study from South India. Indian J Cancer. 51(4), 481\u20136. https:\/\/doi.org\/10.4103\/0019-509X.175303 (2014). PMID: 26842171.","journal-title":"Indian J Cancer."},{"issue":"2","key":"22761_CR32","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s12032-011-9858-3","volume":"29","author":"I Ghosh","year":"2012","unstructured":"Ghosh, I. et al. Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India. Med. Oncol. 29 (2), 1354\u20131360. https:\/\/doi.org\/10.1007\/s12032-011-9858-3 (2012). PMID: 21336987.","journal-title":"Med. Oncol."},{"issue":"1","key":"22761_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s12885-020-06864-8","volume":"20","author":"Y Kitagawa","year":"2020","unstructured":"Kitagawa, Y. et al. Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. BMC Cancer. 20 (1), 358. https:\/\/doi.org\/10.1186\/s12885-020-06864-8 (2020). PMID: 32345249; PMCID: PMC7189469.","journal-title":"BMC Cancer"},{"issue":"12","key":"22761_CR34","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1111\/bcp.14356","volume":"86","author":"P Macaire","year":"2020","unstructured":"Macaire, P. et al. Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic\/pharmacodynamic approach. Br. J. Clin. Pharmacol. 86 (12), 2473\u20132485. https:\/\/doi.org\/10.1111\/bcp.14356 (2020). PMID: 32386071; PMCID: PMC7688541.","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"22761_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia, R., Glaspy, J., Crawford, J. & Aapro, M. Chemotherapy-Induced neutropenia and febrile neutropenia in the US: A beast of burden that needs to be tamed? Oncologist 27 (8), 625\u2013636. https:\/\/doi.org\/10.1093\/oncolo\/oyac074 (2022). PMID: 35552754; PMCID: PMC9355811.","journal-title":"Oncologist"},{"issue":"10","key":"22761_CR36","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.3390\/microorganisms11102547","volume":"11","author":"M Bachlitzanaki","year":"2023","unstructured":"Bachlitzanaki, M. et al. Evaluation of febrile neutropenia in hospitalized patients with neoplasia undergoing chemotherapy. Microorganisms 11 (10), 2547. https:\/\/doi.org\/10.3390\/microorganisms11102547 (2023). PMID: 37894205; PMCID: PMC10609470.","journal-title":"Microorganisms"},{"issue":"7","key":"22761_CR37","doi-asserted-by":"publisher","first-page":"6135","DOI":"10.1007\/s00520-022-07025-2","volume":"30","author":"RL Mahtani","year":"2022","unstructured":"Mahtani, R. L. et al. A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis. Support Care Cancer. 30 (7), 6135\u20136144. https:\/\/doi.org\/10.1007\/s00520-022-07025-2 (2022). PMID: 35426046; PMCID: PMC9009498.","journal-title":"Support Care Cancer"},{"issue":"2","key":"22761_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3816\/CCC.2010.n.013","volume":"9","author":"JR Hecht","year":"2010","unstructured":"Hecht, J. R. et al. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 9(2), 95\u2013101. https:\/\/doi.org\/10.3816\/CCC.2010.n.013 (2010). PMID: 20378503.","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"22761_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clcc.2016.08.008","volume":"16","author":"T Pinter","year":"2017","unstructured":"Pinter, T. et al. Placebo-Controlled trial of pegfilgrastim in patients receiving First-Line FOLFOX\/Bevacizumab or FOLFIRI\/Bevacizumab for locally advanced or metastatic colorectal cancer: final results of the pegfilgrastim and Anti-VEGF evaluation study (PAVES). Clin. Colorectal Cancer 16(2):103\u2013114e3. https:\/\/doi.org\/10.1016\/j.clcc.2016.08.008 (2017). PMID: 28038865.","journal-title":"Clin. Colorectal Cancer"},{"key":"22761_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4103\/ijmpo.ijmpo_31_18","volume":"40","author":"ML Philip","year":"2019","unstructured":"Philip, M. L. et al. Assessment of chemotherapy-induced febrile neutropenia in cancer patients. Indian J. Med. Paediatr. Oncol. 40, 249\u2013256 (2019).","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"22761_CR41","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3332\/ecancer.2021.1188","volume":"15","author":"O Salako","year":"2021","unstructured":"Salako, O. et al. Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria. Ecancermedicalscience 15, 1188. https:\/\/doi.org\/10.3332\/ecancer.2021.1188 (2021). PMID: 33777181; PMCID: PMC7987487.","journal-title":"Ecancermedicalscience"},{"issue":"11","key":"22761_CR42","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1159\/000506109","volume":"43","author":"J Moreira-Pinto","year":"2020","unstructured":"Moreira-Pinto, J. et al. Febrile neutropenia in patients with solid tumors undergoing intravenous chemotherapy. Oncol. Res. Treat. 43 (11), 605\u2013612. https:\/\/doi.org\/10.1159\/000506109 (2020). PMID: 32818937.","journal-title":"Oncol. Res. Treat."},{"issue":"12","key":"22761_CR43","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s00134-002-1528-7","volume":"28","author":"M Darmon","year":"2002","unstructured":"Darmon, M. et al. Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med. 28 (12), 1775\u20131780. https:\/\/doi.org\/10.1007\/s00134-002-1528-7 (2002). PMID: 12447522.","journal-title":"Intensive Care Med."},{"issue":"9","key":"22761_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.12746\/swrccc.v3i9.188","volume":"3","author":"N Hosiriluck","year":"2015","unstructured":"Hosiriluck, N. et al. Prognostic factors for mortality with febrile neutropenia in hospitalized patients. Chronicles [Internet]. 3 (9), 3\u201313 (2015).","journal-title":"Chronicles [Internet]"},{"issue":"25","key":"22761_CR45","first-page":"77","volume":"1","author":"A Rasmy","year":"2017","unstructured":"Rasmy, A., Al Mashiakhi, M. & Ameen, A. Chemotherapy-Induced febrile neutropenia in solid tumours. Gulf J. Oncolog. 1 (25), 77\u201384 (2017). PMID: 29019336.","journal-title":"Gulf J. Oncolog"},{"issue":"6\u20137","key":"22761_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/00365540510038497","volume":"37","author":"K Sigurdardottir","year":"2005","unstructured":"Sigurdardottir, K. et al. A multi-centre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility. Scand J Infect Dis. 37(6\u20137), 455\u201364. https:\/\/doi.org\/10.1080\/00365540510038497 (2005). PMID: 16012006.","journal-title":"Scand J Infect Dis."},{"issue":"5","key":"22761_CR47","doi-asserted-by":"publisher","first-page":"CR304","DOI":"10.12659\/msm.881773","volume":"17","author":"ES Horasan","year":"2011","unstructured":"Horasan, E. S. et al. Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients. Med. Sci. Monit. 17 (5), CR304\u2013CR309. https:\/\/doi.org\/10.12659\/msm.881773 (2011). PMID: 21525814; PMCID: PMC3539578.","journal-title":"Med. Sci. Monit."},{"key":"22761_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/596504","volume":"2015","author":"M Taj","year":"2015","unstructured":"Taj, M. et al. Clinical and Microbiological Profile of Pathogens in Febrile Neutropenia in Hematological Malignancies: A Single Center Prospective Analysis. J Oncol. 2015, 596504. https:\/\/doi.org\/10.1155\/2015\/596504 (2015). PMID: 26290665; PMCID: PMC4531203.","journal-title":"J Oncol."},{"issue":"6","key":"22761_CR49","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s40121-022-00700-1","volume":"11","author":"JR de la Court","year":"2022","unstructured":"de la Court, J. R. et al. The Dutch working party on antibiotic policy (SWAB) recommendations for the diagnosis and management of febrile neutropenia in patients with cancer. Infect. Dis. Ther. 11(6), 2063\u20132098. https:\/\/doi.org\/10.1007\/s40121-022-00700-1 (2022). PMID: 36229765; PMCID: PMC9669256.","journal-title":"Infect. Dis. Ther."},{"issue":"1","key":"22761_CR50","first-page":"39","volume":"7","author":"H Hatamabadi","year":"2019","unstructured":"Hatamabadi, H., Arhami Dolatabadi, A., Akhavan, A. & Safari, S. Clinical characteristics and associated factors of mortality in febrile neutropenia Patients; a cross sectional study. Arch. Acad. Emerg. Med. 7 (1), 39 (2019). PMID: 31555769; PMCID: PMC6732199.","journal-title":"Arch. Acad. Emerg. Med."},{"key":"22761_CR51","first-page":"204993612211383","volume":"9","author":"JM Keck","year":"2022","unstructured":"Keck, J. M. et al. Approach to fever in patients with neutropenia: a review of diagnosis and management. Ther. Adv. Infect. Dis. 9, 20499361221138346 (2022). PMID: 36451936; PMCID: PMC9703488.","journal-title":"Ther. Adv. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22761-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22761-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22761-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:29:40Z","timestamp":1762349380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22761-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22761"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22761-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38787"}}